(E)-2-[[3-methoxy-4-(difluoromethoxy)phenyl-1-oxo-2-propenyl]amino]benzoic acid | 1164144-94-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-2-[[3-methoxy-4-(difluoromethoxy)phenyl-1-oxo-2-propenyl]amino]benzoic acid
• 英文别名: (E)-2-[[3-(3-methoxy-4-(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid；2-[[(E)-3-[4-(difluoromethoxy)-3-methoxyphenyl]prop-2-enoyl]amino]benzoic acid
• CAS: 1164144-94-8
• 化学式: C₁₈H₁₅F₂NO₅
• 分子量: 363.318
• InChiKey: XMGGYBQTSVRRCF-VQHVLOKHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (E)-2-[[3-(3-methoxy-4-(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid piperidinium salt 在 溶剂黄146 作用下， 以 甲醇 、 水 为溶剂， 生成 (E)-2-[[3-methoxy-4-(difluoromethoxy)phenyl-1-oxo-2-propenyl]amino]benzoic acid
  参考文献：
  名称：

  [EN] HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS
  [FR] ANALOGUES HALOGÉNÉS D'AGENTS ANTIFIBROTIQUES

  摘要：

  本发明涉及具有规定的取代基的式(I)的卤代化合物。这些化合物可能作为抗纤维化剂有用。本发明还涉及它们的制备方法。

  公开号：

  WO2009079692A1

文献信息

• METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION
  申请人：OccuRx Pty Ltd

  公开号：EP3485883A1

  公开（公告）日：2019-05-22

  Methods for treating eye diseases associated with inflammation and / or vascular proliferation in subjects are disclosed. The methods include administering therapeutically effective amounts of a tranilast compound, in particular (E)-2-[[3-(3-Methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or (E)-2-[[3,4-Bis(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or pharmaceutically acceptable salts or solvates thereof.

  本发明公开了治疗与受试者炎症和/或血管增生相关的眼部疾病的方法。这些方法包括给药治疗有效量的氨替司特化合物，特别是(E)-2-[[3-(3-甲氧基-4-丙炔氧基)苯基)-1-氧代-2-丙烯基]氨基]苯甲酸或(E)-2-[[3,4-双(二氟甲氧基)苯基)-1-氧代-2-丙烯基]氨基]苯甲酸或其药学上可接受的盐或溶液。
• Methods of treating eye diseases associated with inflammation and vascular proliferation
  申请人：Occurx Pty Ltd

  公开号：US10786510B2

  公开（公告）日：2020-09-29

  Methods for treating eye diseases associated with inflammation and/or vascular proliferation in subjects are disclosed. The methods include administering therapeutically effective amounts of a tranilast compound, in particular (E)-2-[[3-(3-Methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or (E)-2-[[3,4-Bis(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or pharmaceutically acceptable salts or solvates thereof.

  本发明公开了治疗与受试者炎症和/或血管增生相关的眼部疾病的方法。 这些方法包括给药治疗有效量的氨替司特化合物，特别是(E)-2-[[3-(3-甲氧基-4-丙炔氧基)苯基)-1-氧代-2-丙烯基]氨基]苯甲酸或(E)-2-[[3,4-双(二氟甲氧基)苯基)-1-氧代-2-丙烯基]氨基]苯甲酸或其药学上可接受的盐或溶液。
• 3′,4′-Bis-difluoromethoxycinnamoylanthranilate (FT061): An orally-active antifibrotic agent that reduces albuminuria in a rat model of progressive diabetic nephropathy
  作者：Spencer J. Williams、Steven C. Zammit、Alison J. Cox、David M. Shackleford、Julia Morizzi、Yuan Zhang、Andrew K. Powell、Richard E. Gilbert、Henry Krum、Darren J. Kelly

  DOI：10.1016/j.bmcl.2013.09.100

  日期：2013.12

  Cinnamoylanthranilates including tranilast have been identified as promising antifibrotics that can reduce fibrosis occurring in the kidney during diabetes, thereby delaying and/or preventing kidney dysfunction. Structure-activity relationships aimed at improving potency and metabolic stability have led to the discovery of FT061. This compound, which bears a bis-difluoromethoxy catechol, attenuates TGF-beta-stimulated production of collagen in cultured renal mesangial cells (approx 50% at 3 mu M). When dosed orally at 20 mg/kg to male Sprague Dawley rats, FT061 exhibited a high bioavailability (73%), C-max of 200 mu M and T-max of 150 min, and a half-life of 5.4 h. FT061 reduced albuminuria when orally dosed in rats at 200 mg kg/day in a late intervention study of a rat model of progressive diabetic nephropathy. (C) 2013 Elsevier Ltd. All rights reserved.
• HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS
  申请人：Fibrotech Therapeutics PTY LTD

  公开号：EP2220028B1

  公开（公告）日：2016-03-09
• US8624056B2
  申请人：——

  公开号：US8624056B2

  公开（公告）日：2014-01-07